Testing women with endometrial cancer to detect lynch syndrome

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2247-2252

  Kwon, Janice S ^a,b   Scott, Jenna L ^a,b   Gilks, C Blake ^a,b   Daniels, Molly S ^a,b   Sun, Charlotte C ^a,b   Lu, Karen H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HEALTH CARE COST; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PEDIGREE; SENSITIVITY AND SPECIFICITY;

EID: 79957949898     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.9979     Document Type: Article

References (68)

1. Lu HK, Broaddus RR: Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer 4:249-254, 2005
2. Lu KH, Dinh M, Kohlmann W, et al: Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569-574, 2005
3. Syngal S, Weeks JC, Schrag D, et al: Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129:787-796, 1998 (Pubitemid 28522813)
4. Vasen HF, van Ballegooijen M, Buskens E, et al: A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82:1632-1637, 1998 (Pubitemid 28208910)
5. Estimated New Cases for the Most Common Cancers by Sex and Province, Canada, 2010, in Canadian Cancer Society's Steering Committee (ed): Canadian Cancer Statistics 2010. Canadian Cancer Society, Toronto, Ontario, Canada, 2010
6. Altekruse SF, Kosary CL, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, MD, 2010
7. BC Cancer Agency: Lynch syndrome criteria. http://www.bccancer.bc.ca/HPI/ Cancer-ManagementGuidelines/HereditaryCancerProgram/referralinformation/ lynchcriteria.html
8. Lindor NM, Petersen GM, Hadley DW, et al: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 296:1507-1517, 2006 (Pubitemid 44465515)
9. Vasen HF, Moslein G, Alonso A, et al: Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362, 2007 (Pubitemid 46953715)
10. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999 (Pubitemid 29258894)
11. Aaltonen LA: Molecular epidemiology of hereditary nonpolyposis colorectal cancer in Finland. Recent Results Cancer Res 154:306-311, 1998
12. Cunningham JM, Kim CY, Christensen ER, et al: The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780-790, 2001 (Pubitemid 32868523)
13. Debniak T, Kurzawski G, Gorski B, et al: Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 36:49-54, 2000 (Pubitemid 30035343)
14. Hampel H, Stephens JA, Pukkala E, et al: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129:415-421, 2005 (Pubitemid 41096629)
15. Pinol V, Castells A, Andreu M, et al: Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986-1994, 2005
16. Syngal S, Fox EA, Eng C, et al: Sensitivity and specificity of clinical criteria for hereditary nonpolyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641-645, 2000
17. Berends MJ, Wu Y, Sijmons RH, et al: Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 21:4364-4370, 2003 (Pubitemid 46621813)
18. Hampel H, Frankel W, Panescu J, et al: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810-7817, 2006 (Pubitemid 44289242)
19. Lu KH, Schorge JO, Rodabaugh KJ, et al: Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25:5158-5164, 2007 (Pubitemid 350232246)
20. Walsh MD, Cummings MC, Buchanan DD, et al: Molecular, pathologic, and clinical features of early-onset endometrial cancer: Identifying presumptive Lynch syndrome patients. Clin Cancer Res 14:1692-1700, 2008 (Pubitemid 351469453)
21. Neumann PJ, Sandberg EA, Bell CM, et al: Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 19:92-109, 2000
22. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Costeffectiveness in Health and Medicine. JAMA 276:1253-1258, 1996 (Pubitemid 26337709)
23. Desch CE, Benson III AB, Somerfield MR, et al: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512-8519, 2005
24. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening V.1.2010. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#detection
25. World Gastroenterology Organisation/International Digestive Cancer Alliance Practice Guidelines: Colorectal cancer screening. http://www. worldgastroenterology.org/assets/downloads/en/pdf/guidelines/ 06-colorectal-cancer-screening.pdf
26. Richardson LC, Rim SH, Plescia M: Vital Signs: Colorectal cancer screening among adults aged 50-75 years, United States. Morbidity and Mortality Weekly Report 59:1-5, 2010. www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0706a1.htm
27. National Cancer Institute: Screening and Risk Factors Report: Had a sigmoidoscopy or colonoscopy in past 10 years - 2008, all races, female, ages 50+. http://statecancerprofiles.cancer.gov/risk/index.php?risk=23&sex= 2&type=risk&stateFIPS=00&sortVariableName=default&sortOrder= default
28. Kosary CL: Cancer of the corpus uteri, in Ries LAG, Young JL, Keel GE, et al (eds): SEER Survival Monograph: Cancer Survival Among Adults - U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, Bethesda, MD, 2007
29. Ferro SA, Myer BS, Wolff DA, et al: Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 14:717-725, 2008
30. AMA: 2010 CPT codes and Medicare payment information. American Medical Association, Chicago, IL, 2010
31. Cook-Deegan R, DeRienzo C, Carbone J, et al: Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers. Genet Med 12:S15-38, 2010
32. Henry SG, Ness RM, Stiles RA, et al: A cost analysis of colonoscopy using microcosting and time-and-motion techniques. J Gen Intern Med 22:1415-1421, 2007 (Pubitemid 47476694)
33. Lang K, Lines LM, Lee DW, et al: Lifetime and treatment-phase costs associated with colorectal cancer: Evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 7:198-204, 2009
34. Mayo Clinic: Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Screen, Immunostains. Mayo Clinic, Rochester, MN, 2010. http://www. mayomedicallaboratories.com/test-catalog/Fees+and+Coding/83015
35. Mayo Clinic: Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Mutation Screen. Mayo Clinic, Rochester, MN, 2010. http://www.mayomedicallaboratories. com/test-catalog/Fees+and+Coding/83015
36. Yabroff KR, Warren JL, Schrag D, et al: Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care 47:S56-63, 2009
37. Resnick K, Straughn JM Jr, Backes F, et al: Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 114:530-536, 2009
38. Ollikainen M, Abdel-Rahman WM, Moisio AL, et al: Molecular analysis of familial endometrial carcinoma: A manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 23:4609-4616, 2005
39. Goodfellow PJ, Buttin BM, Herzog TJ, et al: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 100:5908-5913, 2003 (Pubitemid 36576906)
40. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al: Ten years after mutation testing for Lynch syndrome: Cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793-4797, 2009
41. Jarvinen HJ, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834, 2000 (Pubitemid 30243745)
42. Vasen HF, Abdirahman M, Brohet R, et al: One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300-2306, 2010
43. de Jong AE, Hendriks YM, Kleibeuker JH, et al: Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665-671, 2006 (Pubitemid 43374516)
44. Cotterchio M, Manno M, Klar N, et al: Colorectal screening is associated with reduced colorectal cancer risk: A case-control study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control 16:865-875, 2005 (Pubitemid 41160050)
45. Boursi B, Halak A, Umansky M, et al: Colonoscopic screening of an average-risk population for colorectal neoplasia. Endoscopy 41:516-521, 2009
46. Rundle AG, Lebwohl B, Vogel R, et al: Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 134:1311-1315, 2008 (Pubitemid 351615369)
47. National Cancer Institute/SEER: Lifetime Risk Tables, SEER Cancer Statistics Review, 1975-2007. Statistical Research and Applications Branch DoCCaPS, National Cancer Institute, Bethesda, MD, 2010
48. Salovaara R, Loukola A, Kristo P, et al: Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18: 2193-2200, 2000 (Pubitemid 30350210)
49. Arias E, Rostron BL, Tejada-Vera B: United States life tables, 2005. Natl Vital Stat Rep 58:1-132, 2008
50. National Cancer Institite/SEER: Endometrial cancer home page. http://www.cancer.gov/cancertopics/types/endometrial
51. Lipton LR, Johnson V, Cummings C, et al: Refining the Amsterdam Criteria and Bethesda Guidelines: Testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 22:4934-4943, 2004 (Pubitemid 46638618)
52. Glanz K, Grove J, Le Marchand L, et al: Underreporting of family history of colon cancer: Correlates and implications. Cancer Epidemiol Biomarkers Prev 8:635-639, 1999 (Pubitemid 29337325)
53. Mitchell RJ, Brewster D, Campbell H, et al: Accuracy of reporting of family history of colorectal cancer. Gut 53:291-295, 2004 (Pubitemid 38125521)
54. Lancaster JM, Powell CB, Kauff ND, et al: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-162, 2007 (Pubitemid 47575743)
55. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004 (Pubitemid 38256271)
56. Westin SN, Lacour RA, Urbauer DL, et al: Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. J Clin Oncol 26:5965-5971, 2008
57. Caldes T, Godino J, Sanchez A, et al: Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Oncol Rep 12:621-629, 2004
58. Halvarsson B, Lindblom A, Rambech E, et al: Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? Virchows Arch 444:135-141, 2004
59. Hampel H, Frankel WL, Martin E, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788, 2008
60. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I: The utility of immunohistochemistry. J Mol Diagn 10:293-300, 2008
61. Cohn DE, Frankel WL, Resnick KE, et al: Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 108:1208-1215, 2006 (Pubitemid 44665417)
62. Modica I, Soslow RA, Black D, et al: Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 31:744-751, 2007 (Pubitemid 46684215)
63. Goldie SJ, Kim JJ, Wright TC: Costeffectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103:619-631, 2004 (Pubitemid 40459019)
64. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 114:1409-1420, 2009
65. Collins VR, Meiser B, Ukoumunne OC, et al: The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: Three years after testing. Genet Med 9:290-297, 2007
66. Hadley DW, Jenkins JF, Steinberg SM, et al: Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J Clin Oncol 26:948-954, 2008 (Pubitemid 351398089)
67. Halbert CH, Lynch H, Lynch J, et al: Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 164:1881-1887, 2004
68. Wagner A, van Kessel I, Kriege MG, et al: Long term follow-up of HNPCC gene mutation carriers: Compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 4:295-300, 2005 (Pubitemid 41795804)